Kornimate/medical-research-clean huggingface dataset:
impact of cerebellar mass resection on pain processing

Conditions: Cerebellar Neoplasm

Summary: the purpose of the study is to evaluate how cerebellar resection surgery may affect pain sensation and the way the brain "reads" pain signals. by measuring brain activity in children and adolescents following surgery, the investigators hope to gain valuable information about pain processing in the brain.

this study is designed to test whether cerebellar resection surgery affects pain pathways in the brain. to participate a participant must (a) have had a cerebellar mass surgically removed, or (b) are a healthy volunteer with no history of pain disorders or mental illness. the study will involve sensory testing and brain imaging using magnetic resonance imaging (mri) sensory testing will be performed using a tub of cold water, as well as a contact thermode capable of delivering hot and cold temperatures. mri brain scanning uses magnetic fields and radio waves to give pictures of the brain without using radiation.

Eligibility criteria:
inclusion criteria for patients: * age 4-18 years old at the time of surgery * resection limited to the cerebellum * within 20 years of surgery * good physical health excluding symptoms directly related to cerebellar resection * no cerebellar-mass directed treatment other than surgical resection inclusion criteria for all subjects: * age 6-38 years old at the time of participation * no paralysis/hemiparesis * no motor deficits that would interfere with performance or required tasks (button press withdraw hand from water bath) * english speaking sufficient to comprehend and provide assent with parental assistance or consent if over the age of 18 * ability to complete mri without sedation exclusion criteria: * claustrophobia * significant medical (e.g. asthma, renal, cardiac, gastrointestinal or immunological) or brain- related disorders (e.g. seizures, autism, psychiatric conditions such as severe depression, psychosis) * metallic or magnetic implants that pose a risk to the participant or to the data quality * weight \> 285 pounds (weight limit of the fmri table) * history of drug abuse or positive drug screen * positive pregnancy screen * use of antidepressants or anticonvulsants, excepting patient usage after resection * significant alcohol history (ingestion of 5 or more glasses (\> 40 oz) of alcohol per week) * tattoos containing metallic ink on the neck, shoulders, upper arm and head (which could heat up in the scanner, and potentially cause blistering or burning) * cardiac pacemakers * aneurysm clips and other vascular stents, filters, clips or other devices * prosthetic heart valves * other prostheses * neuro-stimulator devices * implanted infusion pumps * cochlear (ear) implants * ocular (eye) implants or known metal fragments in eyes * exposure to shrapnel or metal filings (sheet metal workers, welders, and others) * participants that require anesthesia to complete an mri scan * receipt of a medication via transdermal patch

Keywords: cerebellar tumor non-malignant low-grade cerebellar astrocytomas
persistent lymphopenia in liver transplantation and its molecular insights for hepatocellular carcinoma

Conditions: Lymphopenia

Summary: a total of 145 liver transplantation (lt) recipients with hepatocellular carcinoma (hcc) were retrospectively enrolled at kaohsiung chang gung memorial hospital between 2006 and 2019. clinical records from 7 days before lt (pre-lt) to 1 year after lt (post-lt) were analysed. in a prospective study from march 2022 to june 2023, 20 lymphopenia and 25 non-lymphopenia hcc recipients were enrolled, and a phenotypic analysis of peripheral blood lymphocytes was performed using multiparameter flow cytometry.

a total of 145 liver transplantation (lt) recipients with hepatocellular carcinoma (hcc) were retrospectively enrolled at kaohsiung chang gung memorial hospital between 2006 and 2019. clinical records from 7 days before lt (pre-lt) to 1 year after lt (post-lt) were analysed including overall survival, recurrence-free survival, association between clinical parameter with mortality, patient characteristics by pre-lymphopenia and post-lymphopenia levels and lymphocyte status of hcc patients with usage of different immunosuppressants. in prospective study from march 2022 to june 2023, 20 lymphopenia and 25 non-lymphopenia hcc recipients were enrolled, and a phenotypic analysis of peripheral blood lymphocytes was performed using multiparameter flow cytometry to identify the major immune cell subsets and the characteristics of patients in the prospective cohort between pre-lt lymphopenia and non-lymphopenia groups.

Eligibility criteria:
inclusion criteria: * liver transplant patient exclusion criteria: * end-stage liver disease scoring system score (meld score) \> 25 * have received care in the intensive care unit (icu) before transplantation * poor cardiovascular function. * patients suffering active infection. * other complications affecting living donor liver transplantation

Keywords: liver transplantation immune cell subtype immunosuppressant
evaluation of the safety, tolerability, and efficacy of le051 in patients with duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy (DMD)

Summary: the purpose of this study is to evaluate the safety, tolerability, and efficacy of le051 intravenous therapy in dmd patients treated with exon 51 skipping therapy.

this is a single-arm, open-label study to evaluate the safety, tolerability, efficacy, pharmacokinetic, pharmacodynamic, and immune response of le051 after a single intravenous infusion in dmd patients, as well as the long-term safety and efficacy. duchenne muscular dystrophy (dmd) is a progressive neuromuscular disorder arising from mutations in the dystrophin gene, leading to muscle weakness, disability, and premature mortality. le051, an investigational therapy, incorporates a adar recruiting rna expression cassette targeting human exon 51 and is delivered via adeno-associated virus. by inducing exon 51 skipping, le051 holds the potential to treat approximately 13% of dmd patients.

Eligibility criteria:
key inclusion criteria: * male，4-8 years old at the beginning of screening (including boundary values; * dmd subjects with a clinical diagnosis of dmd referred to the duchenne clinical practice guidelines for progressive muscular dystrophy (2020 edition) and whose genetic test results were confirmed to be applicable to exon skipping at no.51. * the subjects and/or his guardian voluntary participate in this trial and can comprehend and sign icf. key exclusion criteria: * clinical signs of heart failure: left ventricular ejection fraction (lvef) \<40%； * the average fvc percentage of the predicted value is less than 40%； * 12 lead ecg qt interval (qtc) \>0.45 seconds.

Keywords: duchenne muscular dystrophy
non-interventional study of the use of alogliptin and alogliptin fixed-dose combinations with pioglitazone and with metformin in standard clinical practice

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to observe alogliptin and alogliptin fixed-dose combinations (fdcs) utilization patterns, as well as clinical response to treatment with alogliptin or alogliptin fdcs, in standard clinical practice.

the drug being studied in this study is called alogliptin and alogliptin fdcs. alogliptin and alogliptin fdcs is being researched to treat people who have diabetes mellitus type 2. this study will look at the glycosylated hemoglobin (hba1c) level dynamics in participants with diabetes mellitus type 2. the study enrolled 593 patients. alogliptin and alogliptin fdcs will be prescribed by the physician as part of participants' t2dm treatment program (independent of participation in this study). this multi-center study will be conducted in china. the overall duration of study for observation will be approximately 6 months, or up to loss to follow-up or death, whichever occurs first. participants will make multiple visits to the clinic as per regular doctor's appointments.

Eligibility criteria:
inclusion criteria: 1. has a diagnosis of t2dm. 2. has made the decision, along with his/her treating physician, to begin treatment with alogliptin or alogliptin fixed-dose combinations (fdcs). 3. has an glycated hemoglobin (hba1c) value recorded at most 3 months before initiation of treatment with alogliptin or alogliptin fdcs. 4. alogliptin or alogliptin fdcs is prescribed according to the approved label for china and hong kong. exclusion criteria: 1. has gestational diabetes or type 1 diabetes mellitus. 2. has used dipeptidyl peptidase-4 inhibitors (dpp-iv inhibitors) or glucagon like peptide-1 agonists (aglp-1) within the 3 months prior to the start of alogliptin or alogliptin fdcs treatment.

Keywords: drug therapy
hydration in children and adolescents with primary headaches

Conditions: Primary Headaches (Includes Migraines, Tension, Cluster Headaches); Hydration; Adolescent; Children

Summary: the aim of this study is to investigate the role of hydration and fluid intake in children and adolescents with primary headaches.

headches are one of the key factors affecting or even limiting the health and well-being of children and adolescents. lifestyle recommendations could help reduce the risk of chronic headaches and improve overall well-being in this population. in clinical practice, adequate fluid intake is one of the general recommendations for headache management. however, scientific literature on the role of hydration and fluid intake in headaches is limited. to date, all studies have been conducted on adults, and no studies have examined this topic in the pediatric population. as the first interventional study investigating the impact of adequate fluid intake on headaches in children and adolescents, our study will make a significant contribution to understanding the role of hydration in headache management and developing recommendations for improving headache control in the pediatric population.

Eligibility criteria:
inclusion criteria: * age 4-18 years. * able to provide informed consent and willing to complete follow-up visits. * primary headaches. * at least 1 headache per month. * presence of headaches for at least 3 months or longer. exclusion criteria: * secondary headaches. * without headaches for 3 months or more.

Keywords: primary headache pediatric children hydration water intake
effects of kangaroo care on circadian rhythm, growth and physiological effects

Conditions: Newborn; Vitality; Sleep; Preterm Labor; Care Pattern, Maternal

Summary: this study was planned to investigate the effect of premature babies receiving regular kangaroo care in the nicu on circadian rhythm, growth and physiological parameters, and breast milk cortisol levels

kangaroo care (kc) may have positive effects on biological phase markers of immature circadian rhythms in newborns. kc provides circadian rhythm development by reducing the stress of newborns. skin-to- skin contact intervention, which is similar to kangaroo care, affects the ß-endorphin concentration, which reduces pain in premature babies, and is known to reduce cortisol levels. kc, which supports exclusive breastfeeding and breastfeeding, can affect the circadian rhythm in newborns by providing information about the time of day to newborns through the increase in breastfeeding rates and the hormones and immune elements contained in breast milk. although there are a limited number of studies in the literature examining the circadian rhythm or sleep-wake cycle of babies in the neonatal intensive care unit, no study has been found examining the circadian rhythm of babies receiving regular kangaroo care using brain imaging methods. in this respect, the study has unique value. in addition, within the scope of the study, regular kangaroo care for three days had a positive effect on the growth and physiological parameters of babies any studies examining the effect of breast milk on cortisol levels no study was found.

Eligibility criteria:
inclusion criteria: * being between 28+0-37 weeks of pregnancy, * birth weight \>1000 g, * apgar score \>7 at the 5th minute after birth, * ability to feed every 2-3 hours exclusion criteria: * getting mechanical ventilation support * undergoing surgery * having diseases and disorders such as congenital brain malformations, meningitis, seizures, encephalopathy, congenital abnormalities, history of intraventricular bleeding, herpes, sepsis and heart or metabolic diseases. * taking medication that affects sleep patterns, such as theophylline, phenobarbital, midazolam, caffeine, fentalnil * having developed intraventricular hemorrhage
nutritional transition in the maghreb and prevention of obesity and non-communicable diseases

Conditions: Iron Deficiency,; Anaemia,; Overweight,; Metabolic Syndrome

Summary: problematic and state of the art obesity and its associated non communicable diseases (ncds) are rising rapidly in middle income countries, such as those in the maghreb (north africa). this progression is related to the context of a nutrition transition (changing food and physical activity environment) and profound changes in technological advances and in society. these societies and their health systems are insufficiently prepared for this evolution, which has enormous health and socioeconomic consequences. in the context of limited resources, the priority has been given on an international level to prevention. but several problems arise: - these countries are still confronted by undernutrition in terms of micronutrient deficiencies, which coexist with obesity and ncds, including at a family level and also individual level. known as the 'double burden', this coexistence is relatively new and has been rarely documented until recently. educational measures could be ineffective in a society where cultural norms do not recognise obesity and where changes in lifestyle are possibly not seen as acceptable. as well as information about citizen's knowledge of risk factors, data on their perceptions and attitudes are indispensable. policies that involve changing the 'obesogenic' environment that individuals occupy is a priority. objectives of the project overall aim: to contribute to the development of preventive strategies for obesity and chronic ncds in the context of a nutrition transition. specific objectives: characterise the nature and size of the double burden (obesity/undernutrition) in regions, families and individuals; estimate the prevalence of biological and behavioural risk factors; characterise the psycho-sociocultural determinants of behaviour.


Eligibility criteria:
inclusion criteria: * to live in the region of the capital city * to give free informed consent exclusion criteria: * pregnancy

Keywords: north africa urban women double burden of malnutrition iron depletion overweight/obesity metabolic syndrome abdominal obesity excess body fat
an interactive program to improve care for children with cf

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to evaluate the impact of an internet based program for children and families (cf.doc) with cystic fibrosis on health outcomes. the program provides for virtual visits, a personal health record, messaging with clinicians and several tools for monitoring self-care behaviors. we anticipate that this intervention will provide for more intensive monitoring and feedback of self-care behaviors and will lead to improved health status and in particular nutritional status

subjects will be drawn from the pool of children who receive their care at the lpch/stanford cystic fibrosis center. a letter will be sent to all eligible patients inviting them to participate in the study. this letter will also be available in the cf clinic. all subjects who agree to participate in the study will have the study described to them by a research assistant either in person or over the phone. informed consent will be obtained all on subjects. subject who elect to participate will be randomized into either an intervention group or a control group . subjects in the intervention group will be given internet access to the program cf.doc. they will also be given training in how to use the program for communication with their clinicians, participating in a virtual visit and using online forms and surveys. subjects in the control group will be advised that they will receive usual care and will have access to cf.doc at the completion of the study. at the beginning of the study and at 3 month intervals subjects will be asked to complete a cystic fibrosis quality of life survey. at the beginning and end of the study all subjects will complete a patient experience questionnaire (caphs 2.0 ccc supplement ) and an cf.doc evaluation survey. as part of their regular care all subjects will also have their nutritional status measured and pulmonary function assessed. subjects in the intervention group will asked to define treatment goals that are important to them (e.g. attending camp or participating in sports) and to define health measures that will help monitor progress in meeting these goals e.g. weekly weights or pulmonary function. subjects in the intervention group will be asked to log onto cf.doc at least one time per month.

Eligibility criteria:
inclusion criteria: patients with cystic fibrosis diagnosed by a sweat chloride analysis and/or testing for the cf gene between the ages of 1 month and 21 years of age. patients must also be english speaking - exclusion criteria: non-english speaking patients -

Keywords: cystic fibrosis; patient education, internet
exposure therapy combined with cortical interventions for crps-ii

Conditions: Complex Regional Pain Syndromes

Summary: consecutive patients with long-standing complex regional pain syndrome ii in a lower limb are treated with graded exposure therapy in vivo in combination with methods targeting cortical reorganisation.

complex regional pain syndrome, crps, is an uncommon but often very handicapping chronic pain syndrome. most often, a single extremity is affected. the diagnosis is subdivided in crps type i where no nerve injury has been identified, and crps type ii when a major nerve injury has been verified. with the exception of spontaneous pain, several of the symptoms related to crps may be connected to the inactivity and immobilization often seen in the history of crps patients. exposure in vivo, a form of behaviour therapy where the patient is gradually confronted with the avoided movements and activities, has been shown safe and effective for patients with crps type i. the present study uses a combination of exposure in vivo and interventions targeting a supposed cortical reorganisation with the hypothesis that the functional impairments would decrease, independent of possible changes in pain levels. consecutive patients with long-standing crps-ii, diagnosed according to the budapest criteria, in a lower limb are included. treatment comprises daily graded exposure therapy in vivo, in combination with methods targeting cortical reorganisation: mirror therapy, desensibilisation training, and sensory re-education. the treatment is implemented at an in-patient ward during four plus four weeks, separated by a home training period of 6-8 weeks.

Eligibility criteria:
inclusion criteria: * complex regional pain syndrome ii exclusion criteria: * severe psychiatric disorder drug abuse

Keywords: behavioural therapy exposure in vivo cortical reorganisation mirror therapy
a journey into participation patterns among metastatic prostate cancer patients

Conditions: Metastatic Prostate Cancer

Summary: taking part in clinical trials usually favors a particular demographic group. but there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. this research will admit a wide range of data on the clinical study experience of metastatic prostate cancer patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. it will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with metastatic prostate cancer.


Eligibility criteria:
inclusion criteria: * patient is at least 18 years of age * diagnosis of metastatic prostate cancer * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * enrolled in another research study * patients with psychiatric illness/social situations that would limit compliance with study requirements * inability to provide written informed consent

Keywords: metastatic prostate cancer
citicoline as neuroprotector in neonates exposed to hypoxia

Conditions: Neonatal Hypoxia

Summary: citicoline as neuroprotector in neonates exposed to hypoxia: a randomized controlled trial

efficacy of citicoline as neuroprotector in neonates exposed to hypoxia: a randomized controlled trial

Eligibility criteria:
inclusion criteria: * neonates with hypoxia. exclusion criteria: * hypoxic ischemic encephalopathy
quantifying ocular surface aberrations after tear film interventions

Conditions: Tear Film Characteristics

Summary: the ca-800 corneal analyzer (visia imaging s.r.l., italy) is a device that can measure small imperfections in the tear film when the eyes are open. the goal of this study is to see if the device can detect changes in the tear film after instillation of an eye drop or when contact lenses are worn.


Eligibility criteria:
inclusion criteria: 1. are at least 17 years of age and have full legal capacity to volunteer. 2. have signed the information consent letter. 3. are willing and able to follow instructions and maintain the appointment schedule. 4. habitually wear spherical soft contact lenses (no multifocal lens, no toric lens wear or extended (overnight) wear). 5. have a vertex-corrected refractive astigmatism of no more than 0.75d in each eye. 6. achieve a best corrected visual acuity of 0.00 logmar or better in each eye. 7. agree to wear the study contact lenses for at least 6 hours. 8. have clear corneas (e.g. no central scars). 9. have no active ocular disease or inflammation. exclusion criteria: 1. are participating in another concurrent clinical research study. 2. have worn any rigid contact lenses in the past 30 days. 3. have been diagnosed with irregular cornea (e.g., keratoconus, etc.). 4. have any known active ocular condition, disease, and/or infection.\* 5. have a systemic or ocular condition that, in the opinion of the investigator, may affect a study outcome variable. 6. have a known sensitivity to the diagnostic sodium fluorescein to be used in the study. 7. have undergone refractive error surgery. 8. are a member of the study team for this study, i.e. are listed on the delegation log for this study.